Correspondence 0001641172-25-003441 from Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc
Date: April 9, 2025 · CIK: 0002025942 · Accession: 0001641172-25-003441
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282686
Letter
Curanex Pharmaceuticals Inc
Jericho Plaza, Suite 101B
Jericho, NY 11753
April 9, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Technology
F Street N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama and Chris Edward
Re:
Curanex Pharmaceuticals Inc - Withdrawal of Acceleration Request Registration Statement on Form S-1, as amended (the "Registration Statement") File No. 333-282686
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on April 8, 2025, in which the undersigned registrant, Curanex Pharmaceuticals Inc, a Nevada corporation (the "Company"), requested acceleration of the effectiveness of the above-referenced Registration Statement on Form S-1 (the "Registration Statement") to 5:00 p.m. Eastern Daylight Time on April 9, 2025, or as soon thereafter as practicable (the "Effective Time"), in accordance with Rule 461 under the Securities Act of 1933, as amended.
The Company is no longer requesting that the Registration Statement be declared effective at the Effective Time and we hereby formally withdraw our request for acceleration of the effective date until further notice from the Company.
Sincerely,
Curanex Pharmaceuticals
Inc
Show Raw Text
CORRESP 1 filename1.htm Curanex Pharmaceuticals Inc 2 Jericho Plaza, Suite 101B Jericho, NY 11753 April 9, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama and Chris Edward Re: Curanex Pharmaceuticals Inc - Withdrawal of Acceleration Request Registration Statement on Form S-1, as amended (the "Registration Statement") File No. 333-282686 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on April 8, 2025, in which the undersigned registrant, Curanex Pharmaceuticals Inc, a Nevada corporation (the "Company"), requested acceleration of the effectiveness of the above-referenced Registration Statement on Form S-1 (the "Registration Statement") to 5:00 p.m. Eastern Daylight Time on April 9, 2025, or as soon thereafter as practicable (the "Effective Time"), in accordance with Rule 461 under the Securities Act of 1933, as amended. The Company is no longer requesting that the Registration Statement be declared effective at the Effective Time and we hereby formally withdraw our request for acceleration of the effective date until further notice from the Company. Sincerely, Curanex Pharmaceuticals Inc By: /s/ Jun Liu Jun Liu Chief Executive Officer